Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Borate U, Tognon CE, Madanat YF, Misra S, Kaempf A, Patel PA, Davis KL, Sun J, Stuani L, Eisenmann ED, Eide CA, Kurtz SE, Watanabe-Smith K, Johnson K, Jager A, Gullaksen SE, Robinson B, Vu T, Plevritis SK, Baker SD, Minnier J, Clement P, Avaylon S, Hayes M, Newell LF, Gandhi AP, Leonard J, Hayes-Lattin B, Vasu S, Cook RJ, Meyers G, Maziarz RT, Traer E, Swords R, Tyner JW, Druker BJ, Saultz JN

Open source

DOI: 10.1016/j.bneo.2026.100205
Published: 2026 May
Container: Blood neoplasia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.bneo.2026.100205,
  title = {Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.},
  author = {Borate U and Tognon CE and Madanat YF and Misra S and Kaempf A and Patel PA and Davis KL and Sun J and Stuani L and Eisenmann ED and Eide CA and Kurtz SE and Watanabe-Smith K and Johnson K and Jager A and Gullaksen SE and Robinson B and Vu T and Plevritis SK and Baker SD and Minnier J and Clement P and Avaylon S and Hayes M and Newell LF and Gandhi AP and Leonard J and Hayes-Lattin B and Vasu S and Cook RJ and Meyers G and Maziarz RT and Traer E and Swords R and Tyner JW and Druker BJ and Saultz JN},
  year = {2026},
  journal = {Blood neoplasia},
  doi = {10.1016/j.bneo.2026.100205},
  url = {https://doi.org/10.1016/j.bneo.2026.100205}
}

RIS

TY  - JOUR
TI  - Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
AU  - Borate U
AU  - Tognon CE
AU  - Madanat YF
AU  - Misra S
AU  - Kaempf A
AU  - Patel PA
AU  - Davis KL
AU  - Sun J
AU  - Stuani L
AU  - Eisenmann ED
AU  - Eide CA
AU  - Kurtz SE
AU  - Watanabe-Smith K
AU  - Johnson K
AU  - Jager A
AU  - Gullaksen SE
AU  - Robinson B
AU  - Vu T
AU  - Plevritis SK
AU  - Baker SD
AU  - Minnier J
AU  - Clement P
AU  - Avaylon S
AU  - Hayes M
AU  - Newell LF
AU  - Gandhi AP
AU  - Leonard J
AU  - Hayes-Lattin B
AU  - Vasu S
AU  - Cook RJ
AU  - Meyers G
AU  - Maziarz RT
AU  - Traer E
AU  - Swords R
AU  - Tyner JW
AU  - Druker BJ
AU  - Saultz JN
PY  - 2026
JO  - Blood neoplasia
DO  - 10.1016/j.bneo.2026.100205
UR  - https://doi.org/10.1016/j.bneo.2026.100205
ER  -

APA

U, B., CE, T., YF, M., S, M., A, K., PA, P., KL, D., J, S., L, S., ED, E., CA, E., SE, K., K, W., K, J., A, J., SE, G., B, R., T, V., SK, P., SD, B., J, M., P, C., S, A., M, H., LF, N., AP, G., J, L., B, H., S, V., RJ, C., G, M., RT, M., E, T., R, S., JW, T., BJ, D., & JN, S. (2026). Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2026.100205

Source records

pubmed · retrieved 2026-09-26T21:47:42.116Z
europe-pmc · retrieved 2026-09-26T21:47:42.119Z